Silicon Valley is no longer content just selling software to drugmakers; it wants to own the laboratory.
Anthropic is searching for a corporate development lead to spearhead biopharma acquisitions and investments. This hiring push signals a major shift in how tech giants view the life sciences. They are moving past simple software licensing.
The physical shift
The company recently bought stealth AI biotech startup Coefficient Bio for $400 million. It also established a physical wet lab in the San Francisco Bay Area.
This is not just about training models on public data. Anthropic wants to run its own biological experiments to feed its algorithms.
Software companies usually avoid the high capital costs of physical labs. But the bottleneck in AI drug discovery is no longer compute power. It is high-quality, proprietary data.
By building labs and buying startups, Anthropic can generate its own data to train “Claude Science.”
The high-risk bet
Partnerships with giants like Novo Nordisk and Bristol Myers Squibb show the industry is paying attention. But biology is notoriously unpredictable.
Running a wet lab introduces massive overhead and physical failure rates that software engineers rarely encounter.
If Anthropic succeeds, it creates a closed loop where AI designs experiments and physical labs validate them instantly. If it fails, it becomes a highly expensive distraction.
The tech industry is about to learn how hard physical biology really is. This is no longer a software game. It is a race for physical infrastructure.
